RAP Registry (Risk Assessment Program Registry)
This is a research study for people who have a higher than average risk of cancer. You will be asked to fill out a Health History Questionnaire and donate a blood sample (and possibly, stored tissue (cells from a tissue sample that was removed in the past). The purpose of this study is to create a registry (a type of study that follows large number of people over time). Information and blood are collected for researchers to study now, and in the future. We will collect information about the health history, family history of cancer and the environment of large numbers of people.
Contact: Yana Chertock
Email: [email protected]
Philadelphia Breast Cancer Family Registry (PBCFR)
The Philadelphia Breast Cancer Family Registry (PBCFR) is one of six international sites of the Breast Cancer Family Registry (B-CFR) funded by the National Cancer Institute. The sites have collaborated over the past 17 years to establish a research resource for use by the scientific community. Health and family history information, blood samples and pathology information are collected from eligible participants and their family members.
Contact: Lisa Bealin
Email: L[email protected]
Prostate Cancer Risk Assessment Program (PRAP)
The Prostate Cancer Risk Assessment Program (PRAP) is a research, education, and screening study for men who are at high risk for prostate cancer. The purpose of the program is to provide men at risk for prostate cancer with education and counseling so they can understand their personal risk. The program also provides yearly prostate cancer screening. Men between the ages of 35-69 who have a family history of prostate cancer or who are African-American, regardless of family history, are eligible for the study. Participation in the study involves an annual PSA blood test and physical exam, donation of blood for research, and completion of medical and family history questionnaires. Each participant receives personalized diet recommendations and a semi-annual newsletter providing up-to-date information on new findings in the field of cancer genetics and risk assessment.